Company intelligence / Profile preview

Molecular Staging

New Haven, Connecticut, United States

Ownership: Private
Development stage: Other

Overview

Molecular Staging was a biotechnology company focused on developing and commercializing advanced nucleic acid and protein amplification technologies. The company's core platform was based on Rolling Circle Amplification (RCA), which enabled highly sensitive detection and quantification of DNA, RNA, and proteins. Their products included kits for whole genome amplification (WGA) and SNP genotyping, which were widely used in genomics research and clinical diagnostics. In 2004, the company was acquired by Qiagen, which integrated its technologies into their market-leading sample preparation and analysis portfolio.

Therapeutic areas: OncologyOther
Modalities: Rolling Circle AmplificationWhole Genome Amplification
Industry: Molecular Diagnostics

Partnerships

Amersham Biosciences

Beyond the preview

Go deeper on Molecular Staging.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecular Staging.

Explore the full profile